Spectacles for Patients With Down Syndrome
Vision, Low
About this trial
This is an interventional treatment trial for Vision, Low
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Down syndrome
Exclusion Criteria:
- Nystagmus (Involuntary beating movement of the eyes)
- Visually significant media opacities (e.g. cataracts or corneal scars)
- Strabismic amblyopia (reduced vision in one eye related to a constant eye-turn)
- Anisometropic amblyopia (reduced vision in one eye related to a long-standing uncompensated difference in prescription between the two eyes)
Sites / Locations
- University of Houston
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Clinical, then Metric #1, then Metric #2
Clinical, then Metric #2, then Metric #1
Metric #1, then Clinical, then Metric #2
Metric #2, then Clinical, then Metric #1
Metric #1, then Metric #2, then Clinical
Metric #2, then Metric #1, then Clinical
Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.